Eliem Therapeutics, Inc. (NASDAQ:ELYM) Shares Purchased by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC grew its holdings in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 145.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,229,292 shares of the company’s stock after acquiring an additional 729,292 shares during the period. Eliem Therapeutics comprises about 3.3% of Ally Bridge Group NY LLC’s investment portfolio, making the stock its 13th biggest holding. Ally Bridge Group NY LLC owned approximately 4.13% of Eliem Therapeutics worth $6,257,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Rhumbline Advisers purchased a new position in Eliem Therapeutics in the second quarter valued at about $59,000. SG Americas Securities LLC acquired a new position in shares of Eliem Therapeutics in the 3rd quarter valued at approximately $60,000. Valence8 US LP purchased a new position in shares of Eliem Therapeutics during the 3rd quarter valued at approximately $61,000. Dimensional Fund Advisors LP acquired a new stake in shares of Eliem Therapeutics during the second quarter worth approximately $89,000. Finally, Chicago Partners Investment Group LLC acquired a new stake in shares of Eliem Therapeutics during the third quarter worth approximately $81,000. 69.76% of the stock is owned by hedge funds and other institutional investors.

Eliem Therapeutics Price Performance

ELYM opened at $3.22 on Thursday. Eliem Therapeutics, Inc. has a 12-month low of $2.35 and a 12-month high of $11.55. The stock has a market capitalization of $95.80 million, a PE ratio of -5.74 and a beta of -0.39. The firm’s fifty day moving average price is $4.69 and its 200 day moving average price is $6.49.

Eliem Therapeutics Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.